Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Hyperfine, Inc. Market Cap
Based on ratings from 3 stock analysts, the Hyperfine, Inc. stock price is expected to increase by 24.58% in 12 months. This is calculated by using the average 12-month stock price forecast for Hyperfine, Inc.. The lowest target is $1 and the highest is $1.5. Please note analyst price targets are not guaranteed and could be missed completely.
About 3 Wall Street analysts have assignedHYPR 1 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect Hyperfine, Inc. to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HYPR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of HYPR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Larry Biegelsen Wells Fargo | Equal-Weight | $1.6 | Maintains | Mar 22, 2024 |
| Young Li Jefferies | Hold | $1.25 | Initiates | Nov 30, 2023 |
| Neil Chatterji B. Riley Securities | Buy | $3.5 | Maintains | Aug 15, 2023 |
| Neil Chatterji B. Riley Securities | Buy | $2.5 | Maintains | Mar 22, 2023 |
| Neil Chatterji B. Riley Securities | Buy | $3.5 | Initiates | Oct 4, 2022 |
| Larry Biegelsen Wells Fargo | Equal-Weight | $2.4 | Downgrade | Aug 11, 2022 |
Evercore ISI Group | Outperform | Initiates | May 31, 2022 | |
Wells Fargo | Overweight | Initiates | Apr 14, 2022 |
When did it IPO
2021
Staff Count
131
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Ms. Maria Sainz
Market Cap
$71.5M
In 2023, HYPR generated $11.0M in revenue, which was a increase of 61.90% from the previous year. This can be seen as a signal that HYPR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Hyperfine presented data from eleven abstracts at the RSNA 2024 Annual Meeting in Chicago, highlighting key findings relevant to its operations.
Why It Matters - Hyperfine's presentation of data at a major radiology conference may indicate advancements in their technology, potentially enhancing market position and impacting stock performance.
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Hyperfine has made strategic appointments to enhance the adoption of its Swoop® system in hospitals and plans to expand into office settings.
Why It Matters - Strategic appointments enhance Hyperfine's growth potential, signaling increased adoption of the Swoop® system, which could boost revenue and market share in healthcare.
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - The IAC has implemented new MRI standards that now permit portable MR scanning at the point of care, effective immediately.
Why It Matters - The inclusion of portable MR scanning at the point of care may drive demand in the medical imaging sector, potentially boosting revenues for companies involved in MRI technology and healthcare services.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Hyperfine, Inc. will present ten scientific abstracts on ultra-low-field imaging at the RSNA 2024 Annual Meeting, showcasing advancements in their imaging technology.
Why It Matters - Hyperfine's presentation of ten scientific abstracts on ultra-low-field imaging could signify advancements in medical imaging technology, potentially boosting investor confidence and market interest.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Hyperfine, Inc. (NASDAQ:HYPR) will hold its Q3 2024 earnings conference call on November 12, 2024, at 4:30 PM ET, featuring key company executives.
Why It Matters - Hyperfine's Q3 earnings call could provide insights into financial performance, strategic direction, and market positioning, influencing stock valuation and investor sentiment.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Hyperfine, Inc. (Nasdaq: HYPR) reported its Q3 2024 financial results and provided a business update, highlighting its FDA-cleared portable MR brain imaging system, the Swoop®.
Why It Matters - Hyperfine's FDA-cleared portable MR system could disrupt brain imaging, impacting market share and revenue potential, influencing investor sentiment and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
